前列腺癌淋巴结转移患者根治性放疗疗效评估:PSMA PET/CT与常规影像的比较分析
这项多中心回顾性研究纳入2009至2021年3家医院接受雄激素剥夺治疗(ADT)联合放疗的淋巴结阳性前列腺癌患者,比较PSMA PET/CT与常规影像分期对疗效的影响。中位随访64.0个月,PSMA PET/CT分期组5年前列腺癌特异性生存率显著高于常规影像组(95.1% vs 76.9%,P=0.01),PSMA PET/CT是更好的前列腺癌特异性生存预测因素。
要点
- PSMA PET/CT分期组5年前列腺癌特异性生存率95.1%,高于常规影像组76.9%(P=0.01)。
- ADT疗程短于24个月与放疗后PSA谷值是PFS的预后因素。
- 早期临床T分期和PSMA PET/CT预测更好的前列腺癌特异性生存。
核心结论
- ADT联合盆腔放疗是淋巴结阳性前列腺癌患者的有效治疗选择。
- PSMA PET/CT在前列腺癌特异性生存方面优于常规影像,强调精确临床分期对接受根治性放疗患者的重要性。
研究设计与样本
- 多中心回顾性研究,纳入2009至2021年3家医院接受常规影像学评估或PSMA PET/CT并接受ADT联合放疗的淋巴结阳性前列腺癌患者。
- 患者接受前列腺和盆腔放疗,并伴随至少6个月的ADT。
- 主要终点为无进展生存期(PFS)和前列腺癌特异性生存期(PCSS)。
主要发现
- 中位随访时间64.0个月,多数患者(64.1%)接受PSMA PET/CT分期。
- 5年PFS率和PCSS率分别为63.7%和83.7%,90例患者(36.3%)观察到疾病进展。
- 多变量分析中,ADT持续时间短于24个月和放疗后PSA谷值是PFS的预后因素。
- 早期临床T分期和PSMA PET/CT预测更好的PCSS。
- PSMA PET/CT分期组5年PCSS率显著高于常规影像组(95.1% vs 76.9%;P=0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated the impact of prostate-specific membrane antigen (PSMA) PET/CT compared with conventional imaging on treatment outcomes for node-positive prostate cancer (PCa) patients who underwent androgen deprivation therapy (ADT) and external radiotherapy (RT). PATIENTS AND METHODS: A multicentric, retrospective study recruited patients with node-positive PCa patients who underwent conventional radiological evaluation or PSMA PET/CT and received ADT and RT at 3 hospitals from 2009 to 2021 were enrolled. Patients underwent prostate and pelvis RT, accompanied by a minimum of 6 months of ADT. The primary endpoints were progression-free survival (PFS) and PCa-specific survival (PCSS). Cox regression analyzed the association of survival with potential prognostic factors, whereas logistic regression identified the predictors of bone and lymph node metastasis. RESULTS: The median follow-up time was 64.0 months. The majority of patients (64.1%) underwent PSMA PET/CT for staging. The 5-year rates of PFS and PCSS were 63.7% and 83.7%, respectively. Disease progression was observed in 90 patients (36.3%). In multivariable analysis, ADT duration of less than 24 months and post-RT prostate-specific antigen (PSA) nadir were prognostic for PFS. Early clinical T stage and PSMA PET/CT predicted better PCSS. Patients staged with PSMA PET/CT had exhibited significantly higher 5-year PCSS rates than compared with those staged with conventional imaging (95.1% vs 76.9%; P = 0.01). Shorter ADT duration and higher PSA levels after RT independently predicted bone metastasis in multivariable logistic regression. Advanced T stage, shorter ADT duration, and higher PSA levels after neoadjuvant ADT predicted nonregional lymph node recurrence. CONCLUSIONS: ADT with pelvis RT is an effective treatment option for node-positive PCa patients. The PSMA PET/CT outperformed conventional imaging in PCSS, emphasizing the importance of precise clinical staging for patients undergoing definitive RT.
引用
- Onal C, Guler OC, Erpolat P, et al. Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging. Clin Nucl Med. 2024. PMID: 38847441. doi:10.1097/RLU.0000000000005284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。